What Kodiak Sciences Inc. does.

Since its founding in 2009, Kodiak Sciences Inc. (“Kodiak,” the “Company,” “we” or “our”) has developed a new technology platform, the Antibody Biopolymer Conjugate (“ABC”) platform, for retinal medicines. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases.

Kodiak has developed three late-stage clinical programs based on its internal discovery and development engine. The lead investigational medicine, tarcocimab tedromer (“Zenkuda” or “KSI-301” or “tarcocimab”), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Zenkuda has a mean ocular half-life in humans of 20 days, approximately three times longer than approved anti-vascular endothelial growth factor ("VEGF") therapies, and is designed to maintain effective drug levels in ocular tissues for longer. Zenkuda is being developed as a mainstay intravitreal biologic monotherapy that provides high immediacy, driven by the enhanced formulation, and high durability, driven by the ABC platform and our science of durability, with the ultimate objective of providing, once approved, a flexible 1-month through 6-month label for all patients with retinal vascular disease (treatment-naïve, treatment-experienced, mild patients and severe patients).

Revenue and profit, by fiscal year.

More on KOD.

• Kodiak Sciences Inc. summary
• Kodiak Sciences Inc. financial statements
• Kodiak Sciences Inc. key metrics
• Kodiak Sciences Inc. health scores and style box
• Kodiak Sciences Inc. earnings
• Kodiak Sciences Inc. dividends
• Kodiak Sciences Inc. valuation
• Kodiak Sciences Inc. ownership and insiders
• Kodiak Sciences Inc. peers

Figures from Kodiak Sciences Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.